Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a $65 price target.

June 17, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a $65 price target, indicating strong confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $65 by a reputable analyst suggests positive sentiment and confidence in the company's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100